Xiaofeng Cheng
Papers
2
Total Citations
9
H-Index
2
About
Dr. Xiaofeng Cheng is a leading urologic oncologist whose research focuses on optimizing treatment strategies for prostate cancer, particularly through the comparative effectiveness of surgical techniques and multimodal therapies. His most impactful work, a 2021 propensity score-matched analysis with 7 citations, rigorously compared robot-assisted radical prostatectomy (RARP) to laparoscopic radical prostatectomy (LRP) for intermediate- and high-risk localized prostate cancer. This study provided critical evidence on functional preservation—specifically urinary continence and erectile function—alongside oncologic control, helping to guide surgical decision-making for high-risk patients. More recently, in 2023, Dr. Cheng investigated oligometastatic prostate cancer, evaluating whether combining RARP with androgen deprivation therapy (ADT) offers superior tumor control over ADT alone, using PSA decline rates as a key metric. This work addresses a pressing clinical question: whether aggressive local therapy benefits patients with limited metastatic spread. By bridging surgical innovation with oncologic outcomes, Dr. Cheng’s research directly impacts clinical protocols, offering clearer pathways for personalized prostate cancer care and improving quality of life for patients facing complex treatment decisions.
Research Focus
Key Achievements
Top Papers
- 1
- 2